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7RESEARCH ARTICLE Open AccessEarly tissue responses to zoledronate, locally
delivered by bone screw, into a compromised
cancellous bone site: a pilot study
Joerg Arnoldi1,2,5*, Antoine Alves3 and Philip Procter1,4Abstract
Background: In fracture treatment, adequate fixation of implants is crucial to long-term clinical performance.
Bisphosphonates (BP), potent inhibitors of osteoclastic bone resorption, are known to increase peri-implant bone
mass and accelerate primary fixation. However, adverse effects are associated with systemic use of BPs. Thus,
Zoledronic acid (ZOL) a potent BP was loaded on bone screws and evaluated in a local delivery model. Whilst
mid- to long-term effects are already reported, early cellular events occurring at the implant/bone interface are not
well described. The present study investigated early tissue responses to ZOL locally delivered, by bone screw, into a
compromised cancellous bone site.
Methods: ZOL was immobilized on fibrinogen coated titanium screws. Using a bilateral approach, ZOL loaded test
and non-loaded control screws were implanted into femoral condyle bone defects, created by an overdrilling
technique. Histological analyses of the local tissue effects such as new bone formation and osteointegration were
performed at days 1, 5 and 10.
Results: Histological evaluation of the five day ZOL group, demonstrated a higher osseous differentiation trend. At
ten days an early influx of mesenchymal and osteoprogenitor cells was seen and a higher level of cellular proliferation
and differentiation (p < 5%). In the ZOL group bone-to-screw contact and bone volume values within the defect
tended to increase. Local drug release did not induce any adverse cellular effects.
Conclusion: This study indicates that local ZOL delivery into a compromised cancellous bone site actively supports
peri-implant osteogenesis, positively affecting mesenchymal cells, at earlier time points than previously reported in the
literature.
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Orthopedic titanium implants such as bone screws have
been widely used for some decades in the treatment of
acute and degenerative bone and joint defects affecting
millions of people worldwide. Their long-term clinical
performance is regulated by their primary and secondary
stability within the host bone [1]. Osteointegration was
identified as a critical parameter for their ultimate success
and great efforts have been made to enhance this process.
For instance, treatments of passivation and/or roughening* Correspondence: joergarnoldi@sunrise.ch
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reproduction in any medium, provided the orhave been employed to enhance peri-implant osteogenesis
[2]. Besides surface modifications and coatings, intended
to enhance primary stability, bone drugs such as bispho-
sphonates, known to be potent inhibitors of osteoclastic
bone resorption, have been used to reduce peri-implant
resorption [3-5]. The underlying hypothesis is that the re-
duction of the peri-implant resorption will result in a net
increase in peri-implant bone mass and stronger second-
ary fixation. The positive impact of bisphosphonates deliv-
ered either orally, intravenously or locally on peri-implant
bone mass has been shown in numerous preclinical and
clinical studies [6-21].
However, adverse effects, such as the appearance of
osteonecrosis in the jaw have also been observed in aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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and intravenously [22]. Furthermore, long-term bis-
phosphonate treatment is thought to adversely impact
on bone metabolism, causing an enhanced risk of atypical
low-energy fractures [23]. To prevent such complications
whilst at the same time positively affecting peri-implant
bone remodelling, innovative methods allowing a local
release of bisphosphonates have been successfully de-
veloped [24]. In particular, local release of Pamidronate
and Ibandronate from fibrinogen coated implants has
been successfully studied in rats [25-28].
The influence of bisphosphonates on bone resorption
varies greatly from compound to compound. In this
study, ZOL was chosen, being at least 100 times more
potent than pamidronate and ibandronate in inhibiting
bone resorption [29]. The high efficacy of ZOL in enhan-
cing implant fixation has been demonstrated in animal
models using histological and biomechanical analysis
[30,31]. Interestingly, only a few publications focus on the
dose response of ZOL and less is known about the impact
of low and high dose applications. Furthermore, the very
early cellular events occurring at the implant/bone inter-
face are not well described and their impact on bone ap-
position remains largely unknown. We hypothesize that
our established in-vivo model allows a better insight into
the early effects of locally applied ZOL and maintain the
intended use of locally applied ZOL in osteosynthesis.
Accordingly the aim of this study was to answer the
following questions: (a) in a bone defect model com-
promised by overdrilling, does a low dose of ZOL de-
livered from a fibrinogen biocoating on a titanium
screw have any effect in the early phase of bone healing?,
(b) does the model enable visualization of the cellular
events taking place sequentially around the drug loaded
screw and (c) does the reduced screw/bone contact
area in an overdrilled bone model have an impact on
the initial mode of action of the drug? The overdrilling
procedure was used to enable consistent modelling of
reduced screw stability comparable to that of compro-
mised cancellous bone [32]. By overdrilling, primary
screw fixation was weakened and the screw/bone con-
tact significantly reduced thereby simulating some as-
pects of an osteopenic situation. The rabbit, known to
be a sensitive and responsive model for evaluating bio-
logical effects, was selected as the means of evaluating
drug related tissue reactions.
Methods
Implants
Control screws
Standard ∅4.0 × 14 mm titanium cancellous bone screws,
characterized by a type 2 annodization and provided by
Stryker (Selzach, Switzerland) were used. Their core diam-
eter was 1.9 mm and the recommended drill diameter forroutine orthopedic applications 2.5 mm. The screws were
sterilized by autoclaving (121°C, 20 min).
ZOL loaded test screws
Identical bone screws were shipped to AddBIO AB
(Linköping, Sweden) for biocoating. Bisphosphonate
(synthetic ZOL, REF ALX-430-153-M025) was provided
by the chemical supplier Alexis (Lausen, Switzerland).
AddBIO biocoated the screws with a fibrinogen multilayer
and subsequently loaded them with 150 ng/cm2 of ZOL in
a process modified from Tengvall [25]. In short, the screws
were incubated first in a solution of 2 mg/ml plasminogen
free fibrinogen for 10 minutes (Haemochrome Diagnostica,
Sweden), and thereafter in a solution of 1 μg/ml ZOL
for 10 minutes [33]. The fibrinogen layer was intended
providing a matrix wherein the ZOL was retained. The
size of the coating was determined by means of ellipso-
metry and revealed a thickness of about 30 nm [25].
There have been no signs of inhomogeneous distribu-
tion of the drug along the screw length [21]. As part of
the internal quality assurance, AddBIO performed bio-
mechanical analyses in synthetic bone substitutes asses-
sing resistance of the coating to mechanical stress. After
drying and single packaging in peel-pouches, the coated
screws were sterilized by γ-irradiation at 17–25 KGy
(Leoni, Switzerland).
Experimental design
This study was conducted in accordance with the pro-
visions of the FDA Good Laboratory Practice (21 CFR,
Part 58, April 01, 2006) and the OECD Good Laboratory
Practices, reference ENV/CM/CHEM (98)11. Permission
was granted to conduct all parts of our animal experi-
ments we applied for (authorization number 59036 by
NAMSA-Biomatech Ethical Committee on November
19, 2009). NAMSA-Biomatech (Chasse-sur-Rhone, France)
is an accredited facility and is registered at the French
Department of Agriculture for animal housing, care and
investigations. Twelve young adult male NZW rabbits
were randomly divided into three groups of four animals
each. Husbandry conditions were in conformance to
the European requirements (Directive EEC/86/609).
The rabbits were individually housed. Relative humidity
was maintained at greater than 30% and temperature
was between 17°C and 21°C. The artificial light cycle
was controlled using an automatic timer (12 hours of
light, 12 hours of dark). Tap water was delivered ad
libitum. Granulated high fibre diet 115 (SAFE, Augy,
France) was provided daily, 200 g per day. In a paired,
randomized approach, one femoral condyle received
the test screw and the opposite side, the control
screw. All surgery was performed under inhalative
O2-isoflurane anesthesia, and all efforts were made to
minimize suffering.
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A longitudinal skin incision was made on the medial
side of the femur, proximal and partly over the knee
joint. The muscles were separated using blunt dissection
to access the femur. The entry point for drilling was set
5 mm proximally to the insertion point of the medial
contralateral ligament (MCL). Drilling of implant cavities
was initiated by introducing a 1.4 mm diameter guide
wire down to the opposite cortex. Overdrilling was
performed using a 3.7 mm diameter cannulated drill,
equipped with a stop at 10 mm. After extensive rinsing
with saline, the screw was inserted manually into the
defect. The screw was then hand tightened. In order to
minimize variations within the implantation proced-
ure, screw insertion and tightening was always done by
the same surgeon. Finally, the wound was closed by
suturing the subcutaneous and intradermal layer with
absorbable thread (Vicryl® 3–0, Ethicon). Two X-rays
(cranio-caudal and latero-medial views) of each femur of
were taken after implantation to check the screw position
(Figure 1A). A subcutaneous injection of Butorphanol
(Torbugesic®, 0.2 mg/kg, Schering-Plough) was admin-
istered after surgery followed by two injections on the
first postoperative day and one daily injection for another
2 days. Subcutaneous injections of an anti-inflammatory
drug (Carprofen, Rimadyl® injectable, Pfizer, 2 mg/kg) and
antibiotic (Enrofloxacin, Baytril®, Bayer, 10 mg/kg) were
administered daily for 10 days post-surgery.
At sacrifice (days 1, 5, and 10), gross examination of the
regions of implantation was performed. Femoral condyles
were harvested and peripheral soft tissues were removed
prior to histopathogical and histomorphometrical analyses.
All experimental groups were blinded and analyses per-
formed by a pathologist not being involved into the study.
Histopathological analysis
Twenty-four bone/implant sites were dehydrated in alcohol
solutions of increasing concentration, cleared in xylene, andA
Figure 1 Representative screw positioning and region of interest (RO
radiological images, demonstrating the appropriate location of the bone sc
B: Histological section, showing the ROI for the histomorphometrical measembedded in polymethylmethacrylate (PMMA). A central
section made through the long axis of the screw was
obtained by using a microcutting and grinding technique
adapted from Donath [34]. Due to the technique, only
one longitudinal ground section could be obtained per
implanted site. The ground sections (20 to 30 μm thickness)
were surface-stained with modified Paragon for quali-
tative, semi-quantitative and quantitative analyses.
Semi-quantitative evaluation of the local tissue effects
was performed based on the ISO 10993–6 standard.
This included evaluation of fibrin, inflammatory reaction
(heterophils, lymphocytes, plasma cells, macrophages,
osteoclasts and giant cells), necrosis, tissue degener-
ation, bone resorption or osteolysis, and finally fibrosis
and fibrous encapsulation. The performance was quali-
tatively and semi-quantitatively assessed by analyzing
bone neoformation, osteointegration and osteoconduction,
osteoblastic and osteoclastic/giant cells, bone remodelling
and neovessels. In the present study, the formation of
loosely vascularized fibro-mesenchymal tissue was de-
fined as fibroplasia.
Histomorphometrical analysis
Histomorphometrical analysis was conducted by digitizing
and examining slides with a ZEISS AXIOSCOPE micro-
scope (magnifications of x5, x10, x25, and x40) equipped
with a colour images analyzing system (software SAMBA
IPS 4.27, SAMBA TECHNOLOGIES, France). The mea-
surements were pixel-based. Automatic segmentation
was based on discriminant color analysis of the tissues.
The bone, screw and soft tissue regions were pixel-masked
with some manual adjustment for correction before
calculation of the tissue areas and contact lengths. The
quantitative analysis was performed to assess the per-
centages of contact and area density parameters within
the screw site. This included bone-to-screw contact, fi-
brin, fibro-mesenchymal tissue and bone lacunae. Bone
healing performance, assessed both qualitatively andROI
B
I) in the lapine medial femoral condyle. A: Post-operative
rew in the lapine bone (cranio-caudal and latero-medial (insert)).
urement.
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formed bone together with indicators of osteointegration
and osteoconduction. An example of the representative
region of interest (ROI) for the histomorphometric
measurements is shown in Figure 1B. Due to the acute
inflammatory events, overbearing at day 1, no histo-
morphometrical measurement was conducted at this
time point.
Statistical analysis
Statistical analysis of the histomorphometrical data was
performed using a Mann and Whitney test (Software
SPSS version 19.0, SPSS inc.) for groups comparison
with a risk established at 5%. The 5 and 10 day test and
control groups were compared for contact and area dens-
ity parameters for fibrin, fibro-mesenchymal tissue and,
bone tissue formation around the implants. A correlation
test (Rho of Spearman) was used to determine the cor-
relation over time between fibrin and fibro-mesenchymal
tissue formation.
Results
Animal follow-up
No major issues were encountered during the surgical
procedure. No major clinical abnormalities were ob-
served during the clinical follow-up of the rabbits.
Macroscopically, at days 1, 5 and 10 after implantation
test and control sites showed slight to marked signs of
inflammatory reaction.
Cranio-caudal and latero-medial X-rays views, performed
in all animals, confirmed the appropriate location of both,Day 1 Day 5
Fibrin and blood clot
(Test ≈ Control)
Heterophils and macrophages
(moderate inflammation)
-Cellular migration-
(Test ≈ Control)
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Figure 2 Chronological events at the screw site in the overdrilled bon
by bold letters).defect and implant in the cancellous bone of the medial
femoral condyle (Figure 1A). The radiographical analysis
of each implanted site at days 5 and 10 after surgery con-
firmed the presence of bone tissue around both test and
control screws.
Histopathological evaluation
At any chosen time point, no adverse events were observed
in either groups. Furthermore, at the screw site, test and
control showed no negative effects on osteoclastic bone
resorption activity. In Figure 2, the cellular events at the
bone defect site from days 1 to day 10 were analysed and
summarized chronologically. Differences observed between
control and test sites are marked in bold in Figure 2.
At day 1, the cavities around the test and control
screw were filled with fibrin and blood clots (Figure 3A,
B). Although, extensive rinsing was performed to remove
bone debris at the time of surgery, numerous small bone
fragments were observed to have accumulated, both at
the screw tip and in the grooves of the screw threads.
Necrotizing bone debris was observed to be compacted
in the bone marrow compartment. A slight to moderate
number of heterophils and macrophages infiltrated both,
bone debris and the fibrin/blood clot matrix.
At day 5, signs of fibrinolysis associated with a slight
to moderate grade of active fibroplasia were observed in
parts of the cavities adjacent to both, test and control
screw (Figure 3C,D). Less necrotizing bone debris was
observed in the bone marrow compartment. A small
number of heterophils and giant cells or osteoclast-like
cells infiltrated the bone debris and the fibrin/blood clotDay 10
hages, Giant 
clasts
mmation)
ntrol)
mesenchymal 
tion
 fibrin matrix)
n-
rol)
uds 
nitor cells
tion-
trol)
Decrease of inflammation
(Test ≈ Control)
Active osteoblasts and woven
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Osteointegration
(Test > Control)
Extensive fibroplasic and 
mesenchymal tissue
(support of bone growth)
(Test > Control)
sis
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Fibrin
(Test <<Control)
e defect (differences between test and control sites are indicated
Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 Representative photomicrographs of undecalcified sections of control (A, C ,E, G and I) or test (ZOL coated) (B, D, F, H and J)
screws after 1 (A and B), 5 (C,E,G and D,F,H) and 10 (I and J) days stained with a modified paragon. Photomicrographs E and F are
respectively high power views of photomicrographs C and D (frames). The signs of repair with formation of fibro-mesenchymal tissue and woven
bone are increased in the test groups without evidence of cellular adverse effects. Yet at 5 days, the test group (picture H) showed more
advanced signs of angiogenesis than the control group (picture G). Osteoclasts remained active around the test implants.
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detected within the peri-implant tissue. Mesenchymal
cells (starred cells), invading the cavities surrounding
test and control screws were very evident (Figure 3E,F).
Within the fibroblastic tissue osseous buds were observed
in 2/4 sites in the control group and in 3/4 sites in the test
group. Osteoblastic activity and osteoid rim formation ap-
peared to be higher within the test group. Noteworthy
was that the formation and maturation of neovessels was
more advanced within the test group (Figure 3G,H).
Ten days after implantation, extensive and substan-
tially vascularized fibro-mesenchymal tissue was ob-
served around the screw (Figure 3I,J). Moderate grade
bone ingrowth was observed within the cavities
around the control screw whilst a moderate to marked
grade of bone ingrowth was observed around the ZOL
treated screw. A slight residue of fibrin and blood
clots was still evident. A major part of the bone debris
was now osteointegrated into newly formed woven
bone which was richly lined by cuboidal (active) oste-
oblasts. The inflammatory reaction diminished, redu-
cing to a slight grade of macrophage and giant or
osteoclast-like cells. Those cells were infiltrating the
fibro-mesenchymal tissue.
Histomorphometrical evaluation
Differences with respect to cumulative contact and area
density parameters at the screw sites were evaluated at
days 5 and 10. The mean quantitative data from the his-
tomorphometrical analysis are summarized in Table 1.Table 1 Histomorphometrical analysis of cumulative contact (
deviation, n = 4 for each group and time-period, p-values (p
Time period
Group
A: Contact (%) Bone
Fibrin
Fibro-mesenchymal tissue
Lacunae
B: Area density (%) Bone
Fibrin
Fibro-mesenchymal tissue
LacunaeContact parameters
Already at an early stage (day 5), the level of bone and
fibro-mesenchymal tissue contact in the test group
showed a more than doubled value compared to the
control group. Furthermore, the percentage of cumula-
tive fibrin and lacunae contact was less dominant in the
test group compared to the control group. This trend
continued to a lesser extent at day 10. Bone and fibro-
mesenchymal tissue contact values were higher and fibrin
and lacunae contact values were lower in the test group
compared to the control group. Overall, signs of enhanced
bone formation activity were observed within the test
group at days 5 and 10. In Table 1A, critical contact
parameters such as the cumulative percentage of bone tis-
sue, fibrin, fibro-mesenchymal tissue, and bone lacunae,
were depicted and statistically significant differences be-
tween test and control groups demonstrated. At day 10,
compared to day 5, the percentage of fibro-mesenchymal
tissue in contact with the screws was significantly increased
(p < 5%) in both groups. The fibro-mesenchymal tissue
growth was inversely correlated (r = −0.97) to the fibrin
showing a significant (p < 5%) drop between days 5 and 10
in both groups. Whereas the fibrin was no longer found in
the test group, the control group showed some residual
peri-implant fibrin at day 10.
Area density parameters
In Table 1B, the above mentioned critical parameters
such as bone tissue, fibrin, fibro-mesenchymal tissue and
bone lacunae were analyzed with regard to cumulativeA) and area density (B) parameter (mean +/− standard
< 5%) highlighted by bold numbers)
Day 5 Day 10
Control Test Control Test
2 ± 1 4 ± 3 10 ± 8 15 ± 8
79 ± 11 62 ± 15 15 ± 15 0
14 ± 10 31 ± 17 73 ± 19 85 ± 8
5 ± 5 3 ± 3 2 ± 2 0
26 ± 8 19 ± 8 28 ± 4 36 ± 4
29 ± 7 20 ± 9 4 ± 5 0
24 ± 15 34 ± 22 44 ± 7 60 ± 1
21 ± 11 28 ± 15 24 ± 8 4 ± 3
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healing was observed in the test group. Showing a
slightly lower bone area density at day 5, the test group
performed over time and even demonstrated an enhanced
level at day 10. Titanium bone screws coated with ZOL
induced a 30% increase in bone area density when
compared to control implants at day 10. Whereas the
bone area density in the control group remained un-
changed between days 5 and 10, the bone area density
in the test group almost doubled within the same time
frame (no statistical difference). The areas occupied by
the bone lacunae developed quite differently in both
groups. Whereas there was no significant difference in
the control sites between days 5 and 10, the test sites
showed a significant decrease in area density over time
(p < 5%). From days 5 to 10, the area density of fibro-
mesenchymal tissue increased in both groups. At day
10, the level was significantly higher for the test compared
to the control group. The reverse result was observed when
analyzing the fibrin. At day 5, the fibrin area significantly
(p < 5%) decreased in both groups. At day 10, as mentioned
above, no fibrin could be detected within the test group.
Discussion
Previous studies have shown that titanium screws coated
with a hydroxyapatite layer, and delivering bisphospho-
nates, show significantly enhanced osteointegration [35].
In the present study, an alternative concept was evalu-
ated in which the fibrinogen biocoating was used as a
carrier for the bisphosphonate. The fibrinogen layer pro-
vided a microporous matrix for hosting ZOL, allowing
the loading of metal implants. Screws loaded with this
biocoating, containing ibandronate and pamidronate,
already demonstrated their efficacy in enhancing implant
fixation in a rat bone model [25]. Furthermore, bio-
mechanical analysis revealed that surface immobilized
ZOL was demonstrated to increase screw stability [36].
These studies demonstrated that the local delivery of
bisphosphonates may be a valid strategy for improving
orthopedic implant fixation. Insertion into cancellous or
even cortical bone sites require a certain mechanical re-
sistance of the drug loaded coating. Abtahi demon-
strated the efficacy of ZOL loaded implants in a dental
application where bone densities and corresponding in-
sertion forces are known to be significantly higher as
compared to cancellous sites [21]. However, the under-
lying mechanism by which ZOL improves orthopedic
implant fixation remains poorly understood. In order to
identify early effects of locally applied ZOL, delivered
from fibrinogen coated screws, a detailed histopatho-
logical and morphometrical evaluation was performed in
a lapine cancellous bone model. Overdrilling was per-
formed in order to reduce the lapine bone strength to be
equivalent to that of compromised human cancellousbone. As a side effect, by enhancing the drill diameter
from 2.5 up to 3.7 mm for applying a ø4.0 mm screw,
the approach significantly reduced the already minimal
risk of affecting the coating during insertion.
Alternate lapine models, inducing a systemic reduction
in bone density were not favourized as a significant osteo-
penia can only be induced by combining an ovariectomy
with the application of drugs such as glucocorticoids [37].
These drugs may significantly interfere with the expected
effects of ZOL and, thus were not indicated. The overdril-
ling enhanced the visualization of some early cellular
events taking place in the corresponding bone cavities at
and near to the screw interface. Three relatively early time
points (1, 5, and 10 days) were chosen for the comparative
evaluation of early bone regeneration.
In the present study, complete disappearance of the
fibrin exudates in the test group was observed at day 10.
The rapid degradation of the biocoating implied that
there was complete release of the ZOL, held in the fi-
brinogen coating, at that time. The ZOL release from
the fibrinogen layer has been tested and published else-
where [28] showing that in vitro, about 60% of the drug
is released within 8 hours. It was estimated that each
implant loaded with 150 ng/cm2, during the coating
procedure, released a dose of 0.263 μg of ZOL. Using
radioactive ZOL solution, and autoradiography of bone
samples, it was demonstrated that, (i) after 1 day of dif-
fusion, the labelled ZOL diffused into the first two mil-
limeters of bone; and that (ii) after 30 days of diffusion,
it had moved towards the periosteal bone and reached
2.5 mm [38]. Assuming a similar diffusion pattern, the
maximum concentration of soluble ZOL that may be
expected in this study is 500 μM. ZOL binds with high
affinity to any mineralized bone surface [39-42] so, ac-
cordingly the in vivo concentration of soluble free ZOL
will be much reduced.
Activated osteoclasts can detach bonded bisphosphonates
from bone mineral surfaces by generating a local acidic
environment [29]. Calvarial osteoblasts and macrophages
are able to uptake the soluble fraction of bisphosphonates
and internalize only the pool of bisphosphonates which
naturally resorbs [43,44]. Accordingly, the impact of a
specific bisphosphonate on these non-resorbing cells
will be highly dependent on its affinity to bone and its
resorption rates [45].
Analyzing the inflammatory events one day after im-
plantation, more macrophages than heterophils could be
detected around the screw implants in both groups.
This is in contrast to other inflammatory scenarios where,
at such an early stage, more heterophils than macrophages
could be observed [46]. These observations may be con-
sistent with a higher level of macrophage recruitment as
part of clearing the high amount of bone debris observed
peri-implant. At day 5, the stimulatory inflammatory
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rather than decreased the number of macrophages present,
as an adaptive response to this stimulation. At day 10,
in both groups, the amount of macrophages similarly
diminished with the clearing of bone debris.
In this study, test and control screw implantation resulted
in similar numbers of osteoblastic, immune and macro-
phage cells appearing at days 5 and 10, suggesting that the
presence of ZOL did not affect these cell populations. With
a low drug dose, the soluble pool of ZOL may not have
reached a concentration that jeopardizes the viability
of osteoblasts and immune cells. In vitro data showed
that osteoblasts from human and mouse origin are not
affected by ZOL, at concentrations below 1 and 10 μM,
respectively [30]. This indicates that even higher doses
may be required to induce significant in vivo effects.
Nevertheless, the dosage of ZOL in the present study
has previously been shown to be effective in a rat model.
In rats, implants coated with hydroxyapatite and deliver-
ing ZOL in the range of 0.2 to 8.5 μg have been shown to
increase mechanical fixation of the implant [30]. In the
present study, the semi-quantitative histopathological ana-
lysis of the test and control groups revealed the presence
of giant cells/osteoclastic cells suggesting that, at the dose
used, ZOL did not affect these cell types. The increase in
bone area density in the test group treated with ZOL may
result from reduced osteoclastic resorptive activity of the
surrounding bone.
Using only one low dose of ZOL might be considered
as a limitation within this study. Further investigations,
extending the drug load are needed to demonstrate any
dose related effects within this model.
The present study aimed an understanding of the early
effects of ZOL on bone ingrowth. Ten days after implant-
ation the release of a low dose of ZOL into compromised
bone resulted in a measurable increase in bone formation.
This observation, although not statistically significant is
nevertheless in line with the results of other experimental
studies, in which local application of bisphosphonates
resulted in biomechanical effects as early as 2 weeks after
implantation [27,47]. Knowing that bone regeneration in
rabbits occurs about three times faster than in other spe-
cies [48] and the fact that ZOL is a more potent drug than
pamidronate and ibandronate, drug related effects may be
expected to occur at an earlier time point.
The present investigation differs from previous studies
using locally applied bisphosphonates in one important
aspect. The overdrilling effect significantly reduced the
initial bone/screw contact, which in consequence, had
significant impact on the initial mode of action of the
drug. In contrast to hydroxyapatite carriers, the fast
degrading fibrinogen layer is known to release the drug
completely within a few days. Within that time frame, the
bone defect is characterized by an inflammatory reactionwhere mesenchymal and immune cells dominate the scene.
Mesenchymal cells may uptake the drug to an even higher
extent than in press-fit applications where, due to the high
affinity to bone, most of the drug binds to the surrounding
bone mineral. With fibrinogen biocoatings, a ‘burst’ release
occurs as the fibrinogen degrades completely within
few days. In this study, uptake of ZOL by attracted cells
enhanced the formation of fibro-mesenchymal tissue and
resulted in membranous bone formation. The amount of
fibro-mesenchymal tissue generated around the test screw
was statistically significantly higher at 10 days compared to
that observed with the control group. The peri-implant
osteogenesis was higher overall (p < 5%) in the ZOL test
group compared to control. These effects reflect a higher
level of cellular proliferation and osseous differentiation
around the loaded implant.
This pilot study was designed to allow first insights
into the early effects of ZOL. Thus, the chosen sample
size as well as the fact that only one section per im-
planted site could be obtained was seen as a limitation.
Further investigations and more detailed analyses are,
however, needed to determine if the observed trend
towards short-term up-regulation will translate into a
statistically significant long-term positive impact on bone
formation and/or strength.
The observations in the present study are in full agree-
ment with the anti-resorptive mechanisms of bisphos-
phonate action described by Aspenberg [24]. According
to his model bisphosphonates protect the bone from
osteoclastic resorption, osteoid being formed around the
implant. Thereafter, this newly formed bone acts as a scaf-
fold for continued bone growth and leads to the formation
of a bony shell.
It is assumed that an increase of bone area density in
screws loaded with ZOL may result from an anabolic
effect of the drug on bone formation. In the present
study, the lack of a control group “titanium screws
coated with fibrinogen only” might be considered a
limitation. In an implantation study in rats, Andersson
[36] evaluated whether fibrinogen-only coated screws
differ from non-coated screws but no such difference
was found. On the other hand, titanium screws coated
with fibrinogen alone have been shown to decrease
bone implant contact by 54% when compared to uncoated
control screws [28]. Thus, we may assume that the ana-
bolic effect of ZOL may be, at least partially, impacted by
the presence of fibrinogen.
Conclusions
In conclusion, this pilot study indicates that local delivery
of a low dose of ZOL, linked to a fibrinogen matrix, on
the surface of titanium bone screws enables early bone
regeneration. Furthermore, it suggests that over the
short term local application ZOL does not affect osteoblast,
Arnoldi et al. BMC Musculoskeletal Disorders 2014, 15:97 Page 9 of 10
http://www.biomedcentral.com/1471-2474/15/97immune and macrophage cell populations. The overdrilled
bone defect model enabled visualization of the early se-
quence of cellular events close to the implant interface.
It also confirmed drug effects in bone that are consist-
ent with those observed in press fit applications. Dose
response studies will be needed to further characterize
early effects and give more insight into the associated
mechanisms of action.
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